2.要約四半期連結財務諸表及び主な注記

(1)要約四半期連結財政状態計算書

 

 

(単位:百万円)

 

前連結会計年度

(2025年12月31日)

当第3四半期連結会計期間

(2026年9月30日)

資産

 

 

流動資産

 

 

現金及び現金同等物

1,387

1,023

営業債権及びその他の債権

374

116

棚卸資産

112

104

その他の流動資産

15

49

流動資産合計

1,890

1,294

非流動資産

 

 

有形固定資産

16

15

使用権資産

97

71

その他の金融資産

141

179

非流動資産合計

254

266

資産合計

2,145

1,560

 

 

 

負債及び資本

 

 

負債

 

 

流動負債

 

 

営業債務及びその他の債務

229

78

リース負債

31

31

その他の流動負債

51

48

流動負債合計

312

159

非流動負債

 

 

繰延税金負債

5

6

リース負債

64

38

その他の非流動負債

11

10

非流動負債合計

80

55

負債合計

393

215

資本

 

 

資本金

836

967

資本剰余金

1,455

1,584

利益剰余金

△521

△1,202

自己株式

△65

△65

その他の資本の構成要素

47

60

資本合計

1,752

1,345

負債及び資本合計

2,145

1,560

 

 

 

 

E3304445970ソレイジア・ファーマ株式会社Solasia Pharma K.K.四半期第3号参考様式 [IFRS](連結)IFRStrueCTE2026-01-012026-09-30Q32026-12-312025-01-012025-09-302025-12-311falsefalsefalse459702025-01-012025-09-30jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember459702025-09-30jpigp_cor:ShareCapitalIFRSMember459702025-09-30jpigp_cor:CapitalSurplusIFRSMember459702025-09-30jpigp_cor:RetainedEarningsIFRSMember459702025-09-30jpigp_cor:TreasurySharesIFRSMember459702025-09-30jpigp_cor:OtherComponentsOfEquityIFRSMember459702025-09-30jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember459702026-01-012026-09-30jpigp_cor:ShareCapitalIFRSMember459702026-01-012026-09-30jpigp_cor:CapitalSurplusIFRSMember459702026-01-012026-09-30jpigp_cor:RetainedEarningsIFRSMember459702026-01-012026-09-30jpigp_cor:TreasurySharesIFRSMember459702026-01-012026-09-30jpigp_cor:OtherComponentsOfEquityIFRSMember459702026-01-012026-09-30jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember459702026-09-30jpigp_cor:ShareCapitalIFRSMember459702026-09-30jpigp_cor:CapitalSurplusIFRSMember459702026-09-30jpigp_cor:RetainedEarningsIFRSMember459702026-09-30jpigp_cor:TreasurySharesIFRSMember459702026-09-30jpigp_cor:OtherComponentsOfEquityIFRSMember459702026-09-30jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember459702025-12-31jpigp_cor:NetChangeInFairValueOfEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember459702026-01-012026-09-30jpigp_cor:NetChangeInFairValueOfEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember459702026-09-30jpigp_cor:NetChangeInFairValueOfEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember459702024-12-31jpigp_cor:NetChangeInFairValueOfEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember459702025-01-012025-09-30jpigp_cor:NetChangeInFairValueOfEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember459702025-09-30jpigp_cor:NetChangeInFairValueOfEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember459702024-12-31459702025-12-31459702025-01-012025-09-30459702025-09-30459702026-01-012026-09-30459702026-09-30459702026-11-12459702024-12-31jpigp_cor:ShareCapitalIFRSMember459702024-12-31jpigp_cor:CapitalSurplusIFRSMember459702024-12-31jpigp_cor:RetainedEarningsIFRSMember459702024-12-31jpigp_cor:TreasurySharesIFRSMember459702024-12-31jpigp_cor:OtherComponentsOfEquityIFRSMember459702024-12-31jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember459702025-12-31jpigp_cor:ShareCapitalIFRSMember459702025-12-31jpigp_cor:CapitalSurplusIFRSMember459702025-12-31jpigp_cor:RetainedEarningsIFRSMember459702025-12-31jpigp_cor:TreasurySharesIFRSMember459702025-12-31jpigp_cor:OtherComponentsOfEquityIFRSMember459702025-12-31jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember459702025-01-012025-09-30jpigp_cor:ShareCapitalIFRSMember459702025-01-012025-09-30jpigp_cor:CapitalSurplusIFRSMember459702025-01-012025-09-30jpigp_cor:RetainedEarningsIFRSMember459702025-01-012025-09-30jpigp_cor:TreasurySharesIFRSMember459702025-01-012025-09-30jpigp_cor:OtherComponentsOfEquityIFRSMemberiso4217:JPYxbrli:sharesiso4217:JPYxbrli:pure